Stingraytx
1 known investors
Stingray Therapeutics develops Vizenpistat (SR-8541A), an ENPP1 inhibitor that blocks the ENPP1 innate immune checkpoint to reactivate the cGAS-STING pathway against cancer. The drug is in clinical trials across multiple oncology indications, including metastatic colorectal cancer, advanced solid tumors, and planned expansions into anal, prostate, and bone cancers.
Investors · 1
Non-dilutive funding · 1 SBIR/STTR award
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2022 | $2M |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Stingraytx do?
- Stingray Therapeutics develops Vizenpistat (SR-8541A), an ENPP1 inhibitor that blocks the ENPP1 innate immune checkpoint to reactivate the cGAS-STING pathway against cancer. The drug is in clinical trials across multiple oncology indications, including metastatic colorectal cancer, advanced solid tumors, and planned expansions into anal, prostate, and bone cancers.
- Who are Stingraytx's investors?
- Stingraytx's investors include Green Park & Golf Ventures.